Helicobacter pylori: Gastric Cancer and Extragastric Malignancies - Clinical aspects

Helicobacter

Volumn 18, Issue S1, 2013, Pages 39-43

  Venerito, Marino ^a   Selgrad, Michael ^a   Malfertheiner, Peter ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Advanced gastric cancer; Colon cancer; Extragastric malignancies; Screening; Treatment

Indexed keywords

CAPECITABINE; CAPECITABINE PLUS OXALIPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROPYRIMIDINE; FLUOROURACIL; IRINOTECAN; LUMINESPIB; PERTUZUMAB; TRASTUZUMAB;

CANCER PREVENTION; CANCER RESISTANCE; CANCER SCREENING; CASE CONTROL STUDY; CLINICAL TRIAL; FIRST DEGREE RELATIVE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; PRIORITY JOURNAL; REVIEW; STOMACH CANCER; STOMACH CARCINOMA;

ADVANCED GASTRIC CANCER; COLON CANCER; EXTRAGASTRIC MALIGNANCIES; SCREENING; TREATMENT;

ANTI-BACTERIAL AGENTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; STOMACH NEOPLASMS;

EID: 84883796834     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/hel.12078     Document Type: Review

References (39)

1. Nagini S. Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol 2012;4:156-69.
2. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Biological agents. Volume 100 B. A review of human carcinogens. IARC Monogr Eval Carcinog Risks Hum 2012;100(Pt B):1-441.
3. Kuipers EJ, Uyterlinde AM, Peña AS, Roosendaal R, Pals G, Nelis GF, et al. Long-term sequelae of Helicobacter pylori gastritis. Lancet 1995;345:1525-8.
4. Varis K, Sipponen P, Laxen F, Samloff IM, Huttunen JK, Taylor PR. The Helsinki Gastritis Study Group. Implications of serum pepsinogen I in early endoscopic diagnosis of gastric cancer and dysplasia. Scand J Gastroenterol 2000;35:950-6.
5. Rampazzo A, Mott GL, Fontana K, Fagundes RB. Gastric adenocarcinoma trends in the central region of Rio Grande do Sul (Southern Brazil): what has changed in 25 years? Arq Gastroenterol 2012;49:178-83.
6. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, et al. ; European Helicobacter Study Group. Management of Helicobacter pylori infection-the Maastricht IV/Florence Consensus Report. Gut 2012;61:646-64.
7. Lee YC, Chen TH, Chiu HM, Shun CT, Chiang H, Liu TY, et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention. Gut 2013;62:676-82.
8. http://globocan.iarc.fr/factsheets/cancers/stomach.asp (accessed: May 23rd 2013).
9. Ma JL, Zhang L, Brown LM, Li JY, Shen L, Pan KF, et al. Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 2012;104:488-92.
10. Dinis-Ribeiro M, Areia M, de Vries AC, Marcos-Pinto R, Monteiro-Soares M, O'Connor A, et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). Endoscopy 2012;44:74-94.
11. Marcos-Pinto R, Carneiro F, Dinis-Ribeiro M, Wen X, Lopes C, Figueiredo C, et al. First-degree relatives of patients with early-onset gastric carcinoma show even at young ages a high prevalence of advanced OLGA/OLGIM stages and dysplasia. Aliment Pharmacol Ther 2012;35:1451-9.
12. Lutz MP, Zalcberg JR, Ducreux M, Ajani JA, Allum W, Aust D, et al. Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer - differential treatment strategies for subtypes of early gastroesophageal cancer. Eur J Cancer 2012;48:2941-53.
13. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. ; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687-97
14. Pazo Cid RA, Antón A. Advanced HER2-positive gastric cancer: current and future targeted therapies. Crit Rev Oncol Hematol 2013;85:350-62.
15. Okines A, Cunningham D, Chau I. Targeting the human EGFR family in esophagogastric cancer. Nat Rev Clin Oncol 2011;8:492-503.
16. Spector NL, Blackwell KL. Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factorreceptor 2-positive breast cancer. J Clin Oncol 2009;27:5838-47.
17. Yamashita-Kashima Y, Iijima S, Yorozu K, Furugaki K, Kurasawa M, Ohta M, et al. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models. Clin Cancer Res 2011;17:5060-70.
18. Cortés J, Fumoleau P, Bianchi GV, Petrella TM, Gelmon K, Pivot X, et al. Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30:1594-600.
19. A Study of Perjeta (Pertuzumab) in Combination With Herceptin (Trastuzumab) and Chemotherapy in Patients With HER2-Positive Metastatic Gastroesophageal Junction or gastric Cancer. ClinicalTrials.gov Identifier: NCT01774786. [WWW document]. URL: http://www.clinicaltrials.gov/ct2/show/study/NCT01774786 (accessed: May 23rd 2013).
20. Travers J, Sharp S, Workman P. HSP90 inhibition: two-pronged exploitation of cancer dependencies. Drug Discov Today 2012;17:242-52.
21. Zuo DS, Dai J, Bo AH, Fan J, Xiao XY. Significance of expression of heat shock protein90alpha in human gastric cancer. World J Gastroenterol 2003;9:2616-18.
22. Lee KH, Lee JH, Han SW, Im SA, Kim TY, Oh DY, et al. Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins. Cancer Sci 2011;102:1388-95.
23. Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, et al. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther 2013;12:509-19.
24. Phase II Trial of AUY922 vs Comparators in Advanced Gastric Cancer. ClinicalTrials.gov Identifier: NCT01084330. [WWW document]. URL: http://www.clinicaltrials.gov/ct2/show/NCT01084330.
25. Phase II of AUY922 in Second-line Gastric Cancer in Combination With Trastuzumab in HER2 Positive Patients. ClinicalTrials.gov Identifier: NCT01402401. [WWW document]. URL: http://www.clinicaltrials.gov/ct2/show/NCT01402401.
26. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005;41:1649-54.
27. PI3K inhibitor BYL719 in combination with the HSP90 inhibitor AUY922 in patients with advanced or metastatic gastric cancer. ClinicalTrials.gov Identifier: NCT01613950. [WWW document]. URL: http://www.clinicaltrials.gov/ct2/show/NCT01613950.
28. Gawin A, Wex T, Lawniczak M, Malfertheiner P, Starzynska T. Helicobacter pylori infection in pancreatic cancer. Pol Merkur Lekarski 2012;32:103-7.
29. Risch HA. Pancreatic cancer: Helicobacter pylori colonization, N-nitrosamine exposures, and ABO blood group. Mol Carcinog 2012;51:109-18.
30. Esmat G, El-Bendary M, Zakarya S, Ela MA, Zalata K. Role of Helicobacter pylori in patients with HCV-related chronic hepatitis and cirrhosis with or without hepatocellular carcinoma: possible association with disease progression. J Viral Hepat 2012;19:473-9.
31. Siupsinskiene N, Jurgutaviciute V, Katutiene I, Janciauskas D, Vaitkus S, Adamonis K. Helicobacter pylori infection in laryngeal diseases. Eur Arch Otorhinolaryngol 2013; Apr 10. [Epub ahead of print]
32. Deng B, Li Y, Zhang Y, Bai L, Yang P. Helicobacter pylori infection and lung cancer: a review of an emerging hypothesis. Carcinogenesis 2013;34:1189-95.
33. Meucci G, Tatarella M, Vecchi M, Ranzi ML, Biguzzi E, Beccari G, et al. High prevalence of Helicobacter pylori infection in patients with colonic adenomas and carcinomas. J Clin Gastroenterol 1997;25:605-7.
34. Wu Q, Yang ZP, Xu P, Gao LC, Fan DM. Association between Helicobacter pylori infection and the risk of colorectal neoplasia: a systematic review and meta-analysis. Colorectal Dis 2013; May 15 [Epub ahead of print].
35. Kapetanakis N, Kountouras J, Zavos C, Michael S, Tsarouchas G, Gavalas E, et al. Re: Helicobacter pylori infection and colorectal cancer risk: evidence from a large population-based case-control study in Germany. Am J Epidemiol 2012;176:566-7.
36. Sonnenberg A, Genta RM. Helicobacter pylori is a risk factor for colonic neoplasms. Am J Gastroenterol 2013;108:208-15.
37. Selgrad M, Bornschein J, Rokkas T, Malfertheiner P. Helicobacter pylori: gastric cancer and extragastric intestinal malignancies. Helicobacter 2012;17(Suppl 1):30-5.
38. Chueca E, Lanas A, Piazuelo E. Role of gastrin-peptides in Barrett's and colorectal carcinogenesis. World J Gastroenterol 2012;18:6560-70.
39. Singh P, Sarkar S, Kantara C, Maxwell C. Progastrin peptides increase the risk of developing colonic tumors: impact on colonic stem cells. Curr Colorectal Cancer Rep 2012;8:277-89.